
Center for



AIDS Research Nicotiana Produced Broadly Neutralizing Monoclonal Antibodies as a Microbicide Strategy

Zhao C¹, Connor-Stroud F¹, Sharma P¹, Oviedo-Moreno P¹, Whaley K², Bohorov O², Moench T³, Anderson DJ⁴ and Villinger F¹.

¹Div of Pathology, Yerkes National Primate Research Center & Dept. of Pathology and Laboratory Medicine, Emory University, Atlanta, GA. ²Mapp Biopharmaceutical, Inc. San Diego, CA.


³ReProtect Inc. Baltimore, MD

⁴Dept of Obstetrics, Gynecology and Microbiology, Boston University, Boston MA.


Background

In the absence of an effective vaccine to prevent the transmission of HIV, alternative prevention methods need to be explored to slow the progression of the epidemics. While condoms have provided good protection from transmission, their use is not necessarily acceptable in select communities and therefore the development of a female controlled efficacious microbicide remains a top priority. Such goal has however been a challenge for HIV as most common approaches have failed or promoted transmission. Our team has taken a different strategy proposing the use of recombinant human monoclonal antibodies (Mabs) broadly neutralizing HIV produced in nicotiana as a cost effective approach.

Methods of Study:




We have studied the HIV neutralizing efficacy of nicotiana produced Mabs VRC01-N and 4E10-N in vitro against panels of HIV and SHIVs. We then tested the pharmacokinetic and distribution of VRC01-N and 4E10-N in the vaginal environment of cynomolgus macaques following administration in 1.5% hydroxyethyl cellulose gel (HEC). Sequential collections of vaginal fluid were performed using TearFlo strips from 5 vaginal sites at 0.5, 4, 24 and 72 hour and cervicovaginal lavages (CVL) at 4, 24 and 72 hour time points. Cynomolgus were chosen due to their relative abundance and the fact that similar to humans and unlike rhesus macaques, they reproductive cycle is continuous instead of seasonal.





Comparison of the neutralizing activity of nicotiana and hybridoma produced VRC01 showed similar neutralization potency against a panel of primary HIV clade C isolates from Africa and SHIV162p3 (clade B).

CVL collected sequentially after administration of 20mg VRC01-N group (n=6) neutralize SHIV162p3 on TZM-bl cells CVL collected sequentially after administration of 18.7mg **4E10-N** group (n=6) neutralize SHIV162p3 on TZM-bl cells




CVL collected at 4 and 24 hours post Mab administration showed potent neutralization of SHIV162p3. At 72 hours the neutralization activity of CVL was decrease in particular for 4E10-N.






Note ---- VRC01-N, MB-HIV02a-N and MB-HIV02b-N are nicotiana-produced monoclonal antibodies bind to CD4 binding site of HIV; HSV8-N is nicotiana-produced monoclonal antibody which against Herpes Simplex Virus 8



a single or repeated daily dose showed that the Mab was restricted to the superficial layers of the stratum corneum with limited penetration by 4 hours and patchy localization by 24 hours, suggesting limited coating of the vaginal epithelium with protective Mabs beyond a few hours.



Cynomolgus macaques (n=15) were divided into 3 groups (n=5), administered either 4E10, VRC01 or control HEC. 30 minutes later, the were exposed macaques to SHIV162p3 vaginally. After 3 challenges, all control animals were infected; while none of the VRC01 (20 mg) monkey were infected. In contrast, 2 of 5 monkeys administered 18.7mg 4E10 became infected. Additional challenges against decreasing Mab doses are being tested.

The neutralization potency of nicotiana produced 4E10 and VRC01 was tested against clade A, B and C SHIVs in TZM-bl cells, showing IC_{50} of 4E10 generally >20 fold higher than the IC_{50} of VRC01 for identical isolates

Conclusion:

We submit that cynomolgus macaques constitute a good model to study not only the pharmacokinetic but also the efficacy of HIV broadly neutralizing Mab base microbicides.

This work was supported by NIH1U19Al096398-02

Results:

Nicotiana produced Mabs neutralization potency are comparable to hybridoma produced Mabs

4E10-N and VRC01-N are broadly neutralizing antibodies which can neutralize different strains of SHIV. While 4E10-N has a broader spectrum, its efficacy is markedly lower than the neutralization potency of VRC01-N

> At 4 hours after administration, the Mab concentration is still high enough to neutralize virus

Innate immune molecule may exist in cynomolgus vagina able to inhibit virus

> Vaginal biopsies show limited penetration of Mab into the vaginal tissue, which was not enhanced by repeated administration

> VRC01-N alone is fully protective at high dose from vaginal SHIV162p3 challenge, while the efficacy of 4E10-N appears limited